ArticleHaematologica2012
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Article in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.Annals of hematology · 2020Trial
- Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.Blood cancer journal · 2025Review
- Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.British journal of haematology · 2024Review
- Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.American journal of hematology · 2023Article
- Article
- Target Therapy for Extramedullary Relapse ofCancers · 2022Review
- MRD Tailored Therapy in AML: What We Have Learned So Far.Frontiers in oncology · 2020Review
- How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?Haematologica · 2019Review
- Review
- MRD in AML: The Role of New Techniques.Frontiers in oncology · 2019Review
- The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.Cancer cell international · 2019Article
- Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients.Medical journal of the Islamic Republic of Iran · 2018Article
- Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.American journal of hematology · 2017Article
- Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.Journal of hematology & oncology · 2016Article
- A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.Molecular diagnosis & therapy · 2015Article
- Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.Blood cancer journal · 2015Article
- Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.Seminars in hematology · 2015Review
- Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.Leukemia · 2015Review
- Transcriptome sequencing reveals CHD1 as a novel fusion partner of RUNX1 in acute myeloid leukemia with t(5;21)(q21;q22).Molecular cancer · 2015Article
- Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Journal of clinical medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations are among the most frequent molecular aberrations in patients with acute myeloid leukemia. We retrospectively analyzed 324 patients with acute myeloid leukemia treated with front-line induction chemotherapy between October 2004 and March 2010. Fifty-six patients had FLT3-ITD mutation at diagnosis. Fifty-one (91%) patients with FLT3-ITD achieved complete remission. Thirteen patients had FLT3 analysis at complete remission. None had FLT3-ITD. Twenty-five (49%) patients with FLT3-ITD relapsed. Of these, 13 (52%) had FLT3-ITD at relapse (3 negative and 9 not done). Among the 201 patients without FLT3-ITD at diagnosis who achieved complete remission, 77 (38%) relapsed among whom 8 (10%) patients acquired FLT3-ITD clone. We conclude that FLT3-ITD mutations are unstable at follow up and may occur for the first time at relapse. Therefore, FLT3-ITD is not a reliable marker for minimal residual disease in acute myeloid leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.